New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …

We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning
in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients …

Traditional conditioning regimens for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) provide suboptimal outcomes, especially for older patients and …

Outcomes of myelofibrosis (MF) with allogeneic stem cell transplantation (allo-SCT) have
improved over the past decade, related in part to advances in supportive treatments and …

Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes
and well‐established molecular drivers. Allogeneic haematopoietic stem cell transplantation …

Compared to reduced-intensity conditioning regimen, myeloablative conditioning (MAC) for
hematopoietic stem cell transplantation (HCT) reduces relapse but is avoided in older …

Background A myeloablative conditioning regimen can be safely given to older patients and
those with comorbidities without increasing nonrelapse mortality (NRM) by fractionating the …

Myelofibrosis is a devastating myeloid malignancy characterized by dysregulation of the JAK-
STAT pathway, resulting in splenomegaly, constitutional symptoms, anemia …

Myeloablative conditioning (MAC) is associated with superior outcomes than reduced-
intensity conditioning in patients undergoing allogeneic hematopoietic stem cell …